Wall Street analysts think Facebook's cryptocurrency payments project will give the company a big boost.Marketsread more
Facebook's reported move into cryptocurrency could amount to the biggest catalyst for digital assets in their decade-long history, some crypto investors say.Bitcoinread more
The Fed is expected to cut rates multiple times, but the reason behind those cuts could have vastly different implications for the market.Marketsread more
"This is going to be the biggest thing that's happened to Facebook in years," says CNBC's Jim Cramer. "It will be vital."Investingread more
A recent Fed survey showed that workers' confidence for finding a new job after losing their current position was at 61.5% in May.Economyread more
These are the stocks posting the largest moves midday.Market Insiderread more
The red-hot market for new public companies in 2019 like Beyond Meat and Chewy could spell bad news for the stock market, Bernstein says.Marketsread more
The "captive carry flight test" evaluates the mock weapon during flight and is the Air Force's latest step amid the budding hypersonic arms race between China and Russia.Politicsread more
It's about time to write off high-growth tech stocks, Goldman warns, saying software carries the highest multiples since the tech bubble.Marketsread more
Profits for major U.S. tobacco companies could be cut in half if the FDA adopts a "maximum nicotine" rule within the next 15 years, according to analysts at Morgan Stanley.Tobaccoread more
Mursi, a top figure in the now-banned Muslim Brotherhood, had been in jail since being toppled by the military in 2013 after barely a year in power following mass protests...World Politicsread more
GlaxoSmithKline PLC: "We don't care where a stock's been, we care where it's going, but it is at $37. It's got a 5 percent yield. [CEO] Emma Walmsley is supposed to be doing a good job. I have not seen what I'd like to see from that company. As far as I'm concerned, there are much better drug stocks to own than Glaxo."
SiteOne Landscape Supply Inc.: "No. You don't want to be there because people don't like housing right now and it's going to be affiliated with the housing group and it just keeps going down. We're going to have to take a big pass."
Abbott Laboratories: "Boy, I think that that one is terrific. That's [CEO] Miles White. He's done a remarkable job. The device business is red-hot. They've got a fantastic balance sheet and it's a big holding of the ActionAlertsPlus.com club."
Disclosure: Cramer's charitable trust owns shares of Abbott Laboratories.